Topic 455: development of a rapid at-home test to detect prostate-specific antigen using self-collected finger stickblood
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91024C00078
- Awardee
-
Inbios International Inc. UEI CNJNQ1GMSN55
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $399,866
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20241 · Posted Jul 7, 2023
- Contract value 88% obligated
-
- $399,866.00 Current, with exercised options
- $454,183.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 17 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Seattle, WA 98104, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Original award | $399,866 |
About this award
This is a $454,183 firm fixed-price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, which is set aside for small businesses, is for the development of a rapid at-home test to detect prostate-specific antigen using self-collected finger stick blood. This contract was awarded under the NCI's Small Business Innovation Research (SBIR) program, which aims to stimulate technological innovation and strengthen the role of small businesses in meeting federal research and development needs. Inbios has previously received federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of diagnostic technologies for infectious diseases, including a rapid test for Chagas disease and a point-of-care antigen detection assay for Ebola Virus Disease.
Quick answers
Who was awarded contract 75N91024C00078?
75N91024C00078 was awarded to Inbios International Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2024.
How much is contract 75N91024C00078 worth?
The government has obligated $399,866 on 75N91024C00078. Its potential value, with all options, is $454,183.
Was contract 75N91024C00078 competed?
The extent of competition for 75N91024C00078 was full and open competition after exclusion of sources. The government received 17 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award